HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment with oral etoposide for childhood recurrent ependymomas.

Abstract
In this study the authors retrospectively evaluated the feasibility and effectiveness of prolonged oral etoposide therapy in children with recurrent ependymoma. Twelve ependymoma patients with documented recurrent or persistent disease were treated between May 1998 and October 2003. All patients were treated monthly with oral VP-16 administered at a dose of 50 mg/m2/d for 21 days, with a 7-day interval between cycles, for a planned minimum number of six cycles. Response (complete plus partial) after two cycles occurred in 5 of the 12 patients (41.6%). Response plus stable disease occurred in 10 of the 12 (83.3%), with a median duration of response or stable disease of 7 months (range 4-30). The median survival was 7 months; the 2-year progression-free survival was 16.7%. These results emphasize that oral etoposide is an attractive option for childhood recurrent ependymomas in terms of administration, tolerability, and neuroradiologic response.
AuthorsAlessandro Sandri, Maura Massimino, Luana Mastrodicasa, Nicola Sardi, Daniele Bertin, Maria Eleonora Basso, Liana Todisco, Alessandra Paglino, Giorgio Perilongo, Lorenzo Genitori, Laura Valentini, Umberto Ricardi, Lorenza Gandola, Felice Giangaspero, Enrico Madon
JournalJournal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 27 Issue 9 Pg. 486-90 (Sep 2005) ISSN: 1077-4114 [Print] United States
PMID16189442 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Etoposide
Topics
  • Administration, Oral
  • Antineoplastic Agents, Phytogenic (administration & dosage)
  • Brain Neoplasms (drug therapy, mortality, pathology)
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Ependymoma (drug therapy, mortality, pathology)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Infant
  • Magnetic Resonance Imaging
  • Male
  • Neoplasm Recurrence, Local (drug therapy, mortality, pathology)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: